

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
August 16, 2016**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Spectrum Pharmaceuticals, Inc.

File No. 1-35006 - CF#33886

Spectrum Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from Exhibits 10.1 and 10.2 to a Form 10-Q filed on May 9, 2013, as modified with respect to Exhibit 10.1 by the same contract refiled with fewer redactions as Exhibit 10.1 to a Form 10-Q filed on August 9, 2016.

Based on representations by Spectrum Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:

Exhibit 10.1	through	May 14, 2019
Exhibit 10.2	through	May 14, 2019

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary